Vericel develops, manufactures, and markets autologous cell-based therapies for patients with serious diseases and conditions. The company markets MACI® (autologous cultured chondrocytes on porcine collagen membrane), a third generation autologous cellularized scaffold product that is indicated for the repair of single or multiple symptomatic, full-thickness cartilage defects of the adult knee, with or without bone involvement.
Enter the email address that you signed up with and we will email you a password reset link.
For your security, this session will expire in due to inactivity. If you want to extend your session, please select the 'Continue' button. If you select the 'Log Out' button or do not respond, your session will automatically close.